[1]刘柏基,熊波波.代谢综合征与良性前列腺增生合并下尿路症状的关系 及治疗研究[J].医学信息,2019,(17):28-31.[doi:10.3969/j.issn.1006-1959.2019.17.010]
 LIU Bai-ji,XIONG Bo-bo.Relationship between Metabolic Syndrome and Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms and Treatment[J].Medical Information,2019,(17):28-31.[doi:10.3969/j.issn.1006-1959.2019.17.010]
点击复制

代谢综合征与良性前列腺增生合并下尿路症状的关系 及治疗研究()
分享到:

医学信息[ISSN:1006-1959/CN:61-1278/R]

卷:
期数:
2019年17期
页码:
28-31
栏目:
综述
出版日期:
2019-09-01

文章信息/Info

Title:
Relationship between Metabolic Syndrome and Benign Prostatic Hyperplasia with Lower Urinary Tract Symptoms and Treatment
文章编号:
1006-1959(2019)17-0028-04
作者:
刘柏基熊波波
云南博亚医院/昆明医科大学第二附属医院泌尿外科,云南 昆明 650000
Author(s):
LIU Bai-jiXIONG Bo-bo
Department of Urology,Yunnan Boya Hospital/the Second Affiliated Hospital of Kunming Medical University, Kunming 650000,Yunnan,China
关键词:
胰岛素抵抗下尿路症状代谢综合征前列腺增生
Keywords:
Key words:Insulin resistanceLower urinary tract symptomsMetabolic syndromeBenign prostatic hyperplasia
分类号:
R697
DOI:
10.3969/j.issn.1006-1959.2019.17.010
文献标志码:
A
摘要:
代谢综合征(MetS)包含胰岛素抵抗,中心性肥胖,血脂异常和高血压。越来越多的证据表明,MetS成为良性前列腺增生(BPH)发展及相关的下尿路症状(LUTS)的男性重要危险因素之一。本文从MetS的定义及其在BPH-LUTS中的流行病学和生物学角度分析MetS与BPH-LUTS的关系,以及α-受体阻滞剂和5α-还原酶抑制剂、双胍类药物、他汀类药物及改变生活方式和减轻体重方式治疗BPH-LUTS合并MetS作一综述,以期为临床治疗提供参考。
Abstract:
Abstract:Metabolic syndrome (MetS) contains insulin resistance, central obesity, dyslipidemia, and hypertension. There is increasing evidence that MetS is one of the major risk factors for men with benign prostatic hyperplasia (BPH) development and associated lower urinary tract symptoms (LUTS). This article analyzes the relationship between MetS and BPH-LUTS from the definition of MetS and its epidemiology and biology in BPH-LUTS, as well as α-blockers and 5α-reductase inhibitors, biguanides, statins. A review of BPH-LUTS combined with MetS in the treatment of drugs and lifestyle changes and weight loss methods, in order to provide a reference for clinical treatment.

参考文献/References:

[1]Russo GI,Regis F,Spatafora P,et al.Association between metabolic syndrome and intravesical prostatic protrusion in patients with benign prostatic enlargement and lower urinary tract symptoms(MIPS Study)[J].BJU Int,2018,121(5):799-804. [2]Lim KB.Epidemiology of clinical benign prostatic hyperplasia[J].Asian J Urol,2017,4(3):148-151. [3]de la Taille A,Descazeaud A,Robert G.How to prevent LUTS due to BPH development and progression[J].Prog Urol,2018,28(15):821-829. [4]张丽霞.代谢综合征与糖尿病和心血管疾病[J].诊断学理论与实践,2007,6(2):172-174. [5]Al Hussein Alawamlh O,Al Hussein Al Awamlh B,Lee RK.Metabolic syndrome and voiding dysfunction[J].Curr Opin Urol,2017,27(5):403-408. [6]杨昌国.美国NCEP专家组的第三次报告中与临床实验室有关的若干问题[J].临床检验杂志,2003,21(2):117-118 [7]纪立农.国际糖尿病联盟代谢综合征全球共识定义解读[J].中华糖尿病杂志,2005,13(3):175-177. [8]张凤龙.代谢综合征对良性前列腺增生患者临床进展性的影响[J].中国民康医学,2016,28(16):1-4,17. [9]Zhao S,Chen C,Chen Z,et al.Relationship between Metabolic Syndrome and Predictors for Clinical Benign Prostatic Hyperplasia Progression and International Prostate Symptom Score in Patients with Moderate to Severe Lower Urinary Tract Symptoms[J].Urol J,2016,13(3):2717-2726. [10]彭涛,庄红雨,姜永光.代谢综合征各组分与良性前列腺增生症的相关性研究[J].中国全科医学,2017,20(2):144-149. [11]Sebastianelli A,Gacci M.Current Status of the Relationship Between Metabolic Syndrome and Lower Urinary Tract Symptoms[J].Eur Urol Focus,2018,4(1):25-27. [12]Rohrmann S,Smit E,Giovannucci E,et al.Association between markers of the metabolic syndrome and lower urinary tract symptoms in the Third National Health and Nutrition Examination Survey (NHANES Ⅲ)[J].Int J Obes(Lond),2005,29(3):310-316. [13]Zou C,Gong D,Fang N,et al.Meta-analysis of metabolic syndrome and benign prostatic hyperplasia in Chinese patients[J].World J Urol,2016(34):281-289. [14]Kwon H,Kang HC,Lee JH.Relationship between predictorsof the risk of clinical progression of benign prostatic hyperplasia and metabolic syndrome in men with moderate to severe lower urinary tract symptoms[J].Urology,2013,81(6):1325-1329. [15]罗文.代谢综合征与下尿路综合征的相关性研究[J].中南大学,2012. [16]Pan JG,Jiang C,Luo R,et al.Association of metabolic syndrome and benign prostatic hyperplasia in Chinese patients of different age decades[J].Urol Int,2014(93):10-16. [17]Haghsheno MA,Mellstr?觟m D,Peeker R,et al.Lower urinary tract symptoms are associated with low levels of serum serotonin,high levels of adiponectin and fasting glucose,and benign prostatic enlargement[J].Scand J Urol,2015,49(2):155-161. [18]Ryl A,Rotter I,Miazgowski T,et al.Metabolic syndrome and benign prostatic hyperplasia:association or coincidence[J].Diabetol Metab Syndr,2015(7):94. [19]Vignozzi L,Gacci M,Maggi M.Lower urinary tract symptoms,benign prostatic hyperplasia and metabolic syndrome[J].Nat Rev Urol,2016,13(2):108-119. [20]Fu Y,Zhou Z,Yang B,et al.The Relationship between the Clinical Progression of Benign Prostatic Hyperplasia and Metabolic Syndrome:A Prospective Study[J].Urol Int,2016,97(3):330-335. [21]Lotti F,Corona G,Vignozzi L,et al.Metabolic syndrome and prostate abnormalities in male subjects of infertile couples[J].Asian J Androl,2014,16(2):295-304. [22]Nayak BS,Sinanan K,Sharma S,et al.Investigating the link between benign prostatic hypertrophy,BMI and type 2 diabetes mellitus[J].Diabetes Metab Syndr,2017,11(Suppl 2):S627-S630. [23]Kupelian V,Araujo AB,Wittert GA,et al.Association of moderate to severe lower urinary tract symptoms with incident type 2 diabetes and heart disease[J].J Urol,2015,193(2):581-586. [24]DeLay KJ,Kohler TS.Testosterone and the Prostate:Artifacts and Truths[J].Urol Clin North Am,2016,43(3):405-412. [25]Ngai HY,Yuen KS,Ng CM,et al.Metabolic syndrome and benign prostatic hyperplasia:An update[J].Asian J Urol,2017,4(3):164-173. [26]Mondul AM,Giovannucci E,Platz EA.A prospective study of obesity,and the incidence and progression of lower urinary tract symptoms[J].J Urol,2014,191(3):715-721. [27]Gacci M,Sebastianelli A,Salvi M,et al.Central obesity is predictive of persistent storage lower urinary tract symptoms(LUTS)after surgery for benign prostatic enlargement:results of a multicentre prospective study[J].BJU Int,2015,116(2):271-277. [28]Chiu YL,Kao S,Lin HC,et al.Benign prostatic enlargement is not associated with diabetes:a population-based study[J].Andrology,2015,3(5):933-936. [29]Martin S,Lange K,Haren MT,et al.Risk factors for progression or improvement of lower urinary tract symptoms in a prospective cohort of men[J].J Urol,2014,191(1):130-137. [30]Russo GI,Castelli T,Urzì D,et al.Connections between lower urinary tract symptoms related to benign prostatic enlargement and metabolic syndrome with its components:a systematic review and meta-analysis[J].Aging Male,2015,18(4):207-216. [31]李培军,张祥华,郭利君,等.高血脂症与良性前列腺增生相关性的临床研究[J].中华外科杂志,2005(2):387-389. [32]Choo MS,Han JH,Shin TY,et al.Alcohol,Smoking,Physical Activity,Protein,and Lower Urinary Tract Symptoms:Prospective Longitudinal Cohort[J].Int Neurourol J,2015,19(3):197-206. [33]Cyrus A,Kabir A,Goodarzi D,et al.Impact of metabolic syndrome on response to medical treatment of benign prostatic hyperplasia[J].Korean J Urol,2014,55(12):814-820. [34]Mosli HH,Esmat A,Atawia RT,et al.Metformin Attenuates Testosterone-Induced Prostatic Hyperplasia in Rats:A Pharmacological Perspective[J].Sci Rep,2015(5):15639. [35]Xu C,Xu Y,Shen Z,et al.Effects of metformin on prostatic tissue of rats with metabolic syndrome and benign prostatic hyperplasia[J].Int Urol Nephrol,2018,50(4):611-617. [36]Wallner LP,Hollingsworth JM,Dunn RL,et al.Hyperglycemia, hyperinsulinemia,insulin resistance,and the risk of BPH/LUTS severity and progression over time in community dwelling black men:the Flint Men's Health Study[J].Urology,2013,82(4):881-886. [37]Zhang X,Zeng X,Dong L,et al.The effects of statins on benign prostatic hyperplasia in elderly patients with metabolic syndrome[J].World J Urol,2015,33(12):2071-2077.

相似文献/References:

[1]吕 宁,徐 昕,黄 永,等.公安民警皮肤软纤维瘤与代谢综合征危险因素相关性研究[J].医学信息,2018,(10):69.[doi:10.3969/j.issn.1006-1959.2018.10.021]
 LV Ning,XU Xin,HUANG Yong,et al.Correlative Study on Skin Soft Fibroma and Risk Factors of Metabolic Syndrome in Public Security Police[J].Medical Information,2018,(17):69.[doi:10.3969/j.issn.1006-1959.2018.10.021]
[2]杨锦龙,刘 欢,吕秋菊,等.非糖尿病患者糖化血红蛋白和胰岛素抵抗与 冠状动脉病变程度的相关性研究[J].医学信息,2018,(10):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
 YANG Jin-long,LIU Huan,LV Qiu-ju,et al.Correlation between Glycosylated Hemoglobin and Insulin Resistance and Severity of Coronary Artery Disease in Non-diabetic Patients[J].Medical Information,2018,(17):93.[doi:10.3969/j.issn.1006-1959.2018.10.028]
[3]谭宏宇,祝清国.当代前列腺动脉栓塞术的文献回顾[J].医学信息,2019,(06):48.[doi:10.3969/j.issn.1006-1959.2019.06.017]
 TAN Hong-yu,ZHU Qing-guo.Literature Review of Contemporary Prostate Artery Embolization[J].Medical Information,2019,(17):48.[doi:10.3969/j.issn.1006-1959.2019.06.017]
[4]李淑娟,王爱芹,杨学军,等.子宫内膜息肉发病相关危险因素临床分析[J].医学信息,2019,(13):119.[doi:10.3969/j.issn.1006-1959.2019.13.035]
 LI Shu-juan,WANG Ai-qin,YANG Xue-jun,et al.Clinical Analysis of Risk Factors Related to the Incidence of Endometrial Polyps[J].Medical Information,2019,(17):119.[doi:10.3969/j.issn.1006-1959.2019.13.035]
[5]谢小莉,李 燕,霍 敏,等.老年2型糖尿病患者轻度认知功能障碍与胰岛素抵抗、 白介素-6的相关性研究[J].医学信息,2019,(15):97.[doi:10.3969/j.issn.1006-1959.2019.15.030]
 XIE Xiao-li,LI Yan,HUO Min,et al.Correlation between Mild Cognitive Impairment and Insulin Resistance and Interleukin-6 in Elderly Type 2 Diabetic Patients[J].Medical Information,2019,(17):97.[doi:10.3969/j.issn.1006-1959.2019.15.030]
[6]郑 文,韦舒静,陈宝峰.男性膀胱颈变化及其与年龄、下尿路症状的相关性研究[J].医学信息,2019,(17):75.[doi:10.3969/j.issn.1006-1959.2019.17.023]
 ZHENG Wen,WEI Shu-jing,CHEN Bao-feng.Changes of Bladder Neck in Males and their Correlation with Age and Lower Urinary Tract Symptoms[J].Medical Information,2019,(17):75.[doi:10.3969/j.issn.1006-1959.2019.17.023]
[7]赵 猛,孙 娟,褚 璇.苯扎贝特改善2型糖尿病合并高甘油三酯血症患者 胰岛素抵抗的临床分析[J].医学信息,2019,(17):145.[doi:10.3969/j.issn.1006-1959.2019.17.048]
 ZHAO Meng,SUN Juan,CHU Xuan.Clinical Analysis of Bezafibrate in Improving Insulin Resistance in Patients with Type 2 Diabetes Mellitus Complicated with Hypertriglyceridemia[J].Medical Information,2019,(17):145.[doi:10.3969/j.issn.1006-1959.2019.17.048]

更新日期/Last Update: 2019-09-01